Lundbeck presents new Phase II asedebart data in Cushing's disease at ENDO 2026

Contributed by: PR Newswire

Tags

LUNDBECK-endo2026data

More Like This

The U.S. FDA grants orphan drug designation for Lundbeck's investigational anti-ACTH monoclonal antibody asedebart for treatment of endogenous Cushing's syndrome

European Commission grants orphan designation for Lundbeck's investigational anti-ACTH monoclonal antibody asedebart for Cushing's syndrome of endogenous origin

Lundbeck receives orphan drug designation in Japan for asedebart for the treatment of patients with congenital adrenal hyperplasia and Cushing's disease

Lundbeck to present new patient data on neuroendocrine and neuroimmunology programs at ENDO 2026

Lundbeck receives orphan drug designation in the US and EU for Lu AG13909 for the treatment of patients with congenital adrenal hyperplasia

Lundbeck presents positive Phase IIb data for bocunebart (Lu AG09222; anti-PACAP mAb) in migraine prevention at the AHS congress

Lundbeck to showcase new neurology data at the American Academy of Neurology Annual Meeting

Lundbeck advances Parkinson's research with new Phase 1b data at AD/PD™ 2026